Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 1
1983 1
1984 2
1985 1
1987 2
1988 1
1989 1
1990 3
1991 5
1992 3
1993 3
1994 4
1995 2
1996 3
1997 2
1999 1
2000 2
2001 1
2003 1
2004 1
2008 1
2010 1
2012 3
2013 6
2014 3
2015 3
2016 3
2017 7
2018 7
2019 4
2020 6
2021 7
2022 15
2023 26
2024 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Hochhaus A, et al. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. N Engl J Med. 2024. PMID: 38820078 Clinical Trial.
Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, Tanaka M, Kako S, Matsuda M, Yokoyama H, Ishikawa Y, Taniguchi Y, Hagihara M, Ozawa Y, Ueda Y, Hirano D, Sakura T, Tsuji M, Kamae T, Fujita H, Hiramoto N, Onoda M, Fujisawa S, Hatta Y, Dobashi N, Nishiwaki S, Atsuta Y, Kobayashi Y, Hayakawa F, Ohtake S, Naoe T, Miyazaki Y. Sugiura I, et al. Among authors: hiramoto n. Blood Adv. 2022 Jan 25;6(2):624-636. doi: 10.1182/bloodadvances.2021004607. Blood Adv. 2022. PMID: 34516628 Free PMC article. Clinical Trial.
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y, Tobiasson M, Sato S, Bernard E, Ohtake S, Takeda J, Creignou M, Zhao L, Kusakabe M, Shibata Y, Nakamura N, Watanabe M, Hiramoto N, Shiozawa Y, Shiraishi Y, Tanaka H, Yoshida K, Kakiuchi N, Makishima H, Nakagawa M, Usuki K, Watanabe M, Imada K, Handa H, Taguchi M, Kiguchi T, Ohyashiki K, Ishikawa T, Takaori-Kondo A, Tsurumi H, Kasahara S, Chiba S, Naoe T, Miyano S, Papaemanuil E, Miyazaki Y, Hellström-Lindberg E, Ogawa S. Nannya Y, et al. Among authors: hiramoto n. Blood Adv. 2023 Jul 25;7(14):3624-3636. doi: 10.1182/bloodadvances.2022009564. Blood Adv. 2023. PMID: 36989067 Free PMC article.
Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation.
Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, Eto T, Nagafuji K, Hiramoto N, Matsuoka KI, Maruyama Y, Ota S, Ishikawa J, Kawakita T, Akasaka T, Kamimura T, Hino M, Fukuda T, Atsuta Y, Yakushijin K. Fuji S, et al. Among authors: hiramoto n. Br J Haematol. 2024 Mar;204(3):959-966. doi: 10.1111/bjh.19228. Epub 2023 Nov 30. Br J Haematol. 2024. PMID: 38037468
Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect.
Umino K, Morita K, Ikeda T, Kawaguchi SI, Nagayama T, Ito S, Minakata D, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kimura SI, Kako S, Doki N, Ozawa Y, Mori Y, Eto T, Hiramoto N, Nakamae H, Kanda J, Ichinohe T, Atsuta Y, Nakasone H, Morishima S, Kanda Y. Umino K, et al. Among authors: hiramoto n. Blood. 2023 Sep 14;142(11):1008-1021. doi: 10.1182/blood.2023019799. Blood. 2023. PMID: 37363859 Free article.
Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma.
Nakaya Y, Nakamae H, Nishikubo M, Kondo E, Fukuda T, Hiramoto N, Mori Y, Nagafuji K, Eto T, Onishi Y, Uchida N, Ishikawa J, Matsuoka KI, Yui S, Takase K, Kawakita T, Kanda J, Ichinohe T, Atsuta Y, Kako S. Nakaya Y, et al. Among authors: hiramoto n. Bone Marrow Transplant. 2024 May;59(5):630-636. doi: 10.1038/s41409-024-02229-y. Epub 2024 Feb 14. Bone Marrow Transplant. 2024. PMID: 38355911
The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation.
Shimazu Y, Kanda J, Suzuki K, Wada A, Kikuchi T, Ikeda T, Tsukada N, Miwa A, Itagaki M, Kako S, Nishiwaki K, Ota S, Fujiwara SI, Kataoka K, Doki N, Sawa M, Hiramoto N, Nishikawa A, Imai T, Ichinohe T, Kanda Y, Atsuta Y, Kawamura K. Shimazu Y, et al. Among authors: hiramoto n. Cancer Sci. 2024 Jul;115(7):2384-2395. doi: 10.1111/cas.16198. Epub 2024 May 16. Cancer Sci. 2024. PMID: 38757410 Free PMC article.
Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide.
Shimomura Y, Komukai S, Kitamura T, Sobue T, Akahoshi Y, Kanda J, Ohigashi H, Nakamae H, Hiramoto N, Nagafuji K, Tanaka T, Eto T, Ota S, Maruyama Y, Akasaka T, Matsuoka KI, Mori Y, Fukuda T, Atsuta Y, Terakura S. Shimomura Y, et al. Among authors: hiramoto n. Bone Marrow Transplant. 2024 Jan;59(1):66-75. doi: 10.1038/s41409-023-02142-w. Epub 2023 Oct 28. Bone Marrow Transplant. 2024. PMID: 37898725
Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis.
Suzuki K, Shimazu Y, Minakata D, Ikeda T, Takahashi H, Tsukada N, Kanda Y, Doki N, Nishiwaki K, Miwa A, Sawa M, Kataoka K, Hiramoto N, Ota S, Itagaki M, Ichinohe T, Atsuta Y, Yano S, Kawamura K; working group of the Japan Society for Transplantation and Cellular Therapy. Suzuki K, et al. Among authors: hiramoto n. Transplant Cell Ther. 2023 Nov;29(11):688.e1-688.e13. doi: 10.1016/j.jtct.2023.08.006. Epub 2023 Aug 11. Transplant Cell Ther. 2023. PMID: 37574125 Free article.
Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
Kato K, Sugio T, Ikeda T, Yoshitsugu K, Miyazaki K, Suzumiya J, Yamamoto G, Kim SW, Ikegame K, Uehara Y, Mori Y, Ishikawa J, Hiramoto N, Eto T, Nakazawa H, Kobayashi H, Serizawa K, Onizuka M, Fukuda T, Atsuta Y, Suzuki R. Kato K, et al. Among authors: hiramoto n. Bone Marrow Transplant. 2024 Mar;59(3):306-314. doi: 10.1038/s41409-023-02156-4. Epub 2023 Dec 15. Bone Marrow Transplant. 2024. PMID: 38102209
142 results